<sup>68</sup>Ga‐<scp>PSMA PET</scp>/<scp>CT</scp> for the detection of bone metastases in prostate cancer: a systematic review of the published literature

Zacho, Helle D; Nielsen, Jesper; Haberkorn, Uwe; Stenholt, Louise; Petersen, Lars Jelstrup

doi:10.1111/cpf.12480

Cited by 61 publications

(42 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CTT1057 demonstrated improved sensitivity for bone and lymph node detection compared with conventional bone scanning and CT of the chest, abdomen, or pelvis. This result is consistent with other reports that showed PSMA PET to have improved detection rates of bone metastases over bone scanning (14). Of the 56 positive bone metastases detectable on CTT1057, 44 (78.5%) were detectable on bone scanning.…”

Section: Qualitative and Quantitative Image Analysis For Cohort Bsupporting

confidence: 92%

Phase I Study of CTT1057, an ¹⁸F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

et al. 2018

View full text Add to dashboard Cite

Section: Qualitative and Quantitative Image Analysis For Cohort Bsupporting

confidence: 92%

Phase I Study of CTT1057, an ¹⁸F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

et al. 2018

View full text Add to dashboard Cite

“…The fact that the 68 Ga-PSMA PET misses lymph node metastases is highlighted by a lower per-node sensitivity, which is in the range of 24.4-66.67%. Lymph node metastases can be missed because of the lack of PSMA expression in 0-9% of primary prostate tumours and lymph node metastases [57,58]. Moreover, 68 Ga-PSMA PET misses small lymph node metastases [10,12,15,25,27].…”

Section: Discussionmentioning

confidence: 99%

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Luiting¹,

Leeuwen

Busstra³

et al. 2019

BJU International

View full text Add to dashboard Cite

ObjectivesTo review the literature to determine the sensitivity and specificity of gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) positron-emission tomography (PET) for detecting pelvic lymph node metastases in patients with primary prostate cancer (PCa), and the positive predictive value in patients with biochemical recurrence (BCR) after initial curative treatment, and, in addition, to determine the detection rate and management impact of 68 Ga-PSMA PET in patients with BCR after radical prostatectomy (RP). Materials and MethodsWe performed a comprehensive literature search. Search terms used in MEDLINE, EMBASE and Science Direct were '(PSMA, 68 Ga-PSMA, 68 Gallium-PSMA, Ga-68-PSMA or prostate-specific membrane antigen)' and '(histology, lymph node, staging, sensitivity, specificity, positive predictive value, recurrence, recurrent or detection)'. Relevant abstracts were reviewed and full-text articles obtained where possible. References to and from obtained articles were searched to identify further relevant articles. ResultsNine retrospective and two prospective studies described the sensitivity and specificity of 68 Ga-PSMA PET for detecting pelvic lymph node metastases before initial treatment, which ranged from 33.3% to 100% and 80% to 100%, respectively. In eight retrospective studies, the positive predictive value of 68 Ga-PSMA PET in patients with BCR before salvage lymph node dissection ranged from 70% to 100%. The detection rate of 68 Ga-PSMA PET in patients with BCR after RP in the PSA subgroups <0.2 ng/mL, 0.2-0.49 ng/mL and 0.5 to <1.0 ng/ mL ranged from 11.3% to 50.0%, 20.0% to 72.7% and 25.0% to 87.5%, respectively. ConclusionThe review results showed that 68 Ga-PSMA PET had a high specificity for the detection of pelvic lymph node metastases in primary PCa. Furthermore, 68 Ga-PSMA PET had a very high positive predictive value in detecting lymph node metastases in patients with BCR. By contrast, sensitivity was only moderate; therefore, based on the currently available literature, 68 Ga-PSMA PET cannot yet replace pelvic lymph node dissection to exclude lymph node metastases. In the salvage phase, 68 Ga-PSMA PET had both a high detection rate and impact on radiotherapy planning in early BCR after RP. Keywords 68Ga-PSMA PET/CT, pelvic lymph node dissection, detection rate, pelvic lymph node metastases, #ProstateCancer, #PCSM Use of 68Ga-PSMA PET/CT after RP: review IQR, interquartile range; LNM, lymph node metastases. *Gallium-68 prostate-specific membrane antigen positron-emission tomography ( 68 Ga-PSMA PET)/MRI was used instead of 68 Ga-PSMA PET/CT. 208

show abstract

“…There are of course other nuclear medicine modalities available for the detection and characterization of bone metastases in prostate cancer patients. 68 Ga-prostate specific membrane antigen (PSMA), PET/CT [18,19]. Nonetheless, in many countries, 68 Ga-PSMA, F-Choline and 18 F-NaF PET are not widely available for primary staging due to cost and reimbursement issues, as impact on patient management and cost-effective studies are not yet available [20].…”

Section: Discussionmentioning

confidence: 99%

Quantitative Bone SPECT/CT: High Specificity for Identification of Prostate Cancer Bone Metastases

Tabotta

Jre

Schaefer

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose: Bone scintigraphy with 99mTc-labeled diphosphonates can identify prostate cancer bone metastases with high sensitivity, but relatively low specificity, because benign conditions such as osteoarthritis can also trigger osteoblastic reactions. We aimed to investigate the diagnostic performance of 99mTc-2,3-dicarboxy propane-1,1-diphosphonate (99mTc-DPD) uptake quantification by single-photon emission computed tomography coupled with computed tomography (SPECT/CT) for distinguishing prostate cancer bone metastases from spinal and pelvic osteoarthritic lesions.Methods: We retrospectively assessed 26 bone scans from 26 patients with known prostate cancer bone metastases and 13 control patients with benign spinal and pelvic osteoarthritic changes without known neoplastic disease. Quantitative SPECT/CT (xSPECT, Siemens Symbia Intevo, Erlangen, Germany) was performed and standardized uptake values (SUVs) were quantified with measurements of SUVmax and SUVmean (g/mL) in all bone metastases for the prostate cancer group and in lumbar and pelvic osteoarthritic changes for the control group. We used receiver operating characteristics (ROC) curves to determine the optimum SUVmax cutoff value to distinguish between bone metastases and benign spinal and pelvic lesions. Results: In total, 264 prostate cancer bone metastases were analyzed, showing a mean SUVmax and SUVmean of 34.6±24.6 and 20.8±14.7 g/mL, respectively. In 24 spinal and pelvic osteoarthritic lesions, mean SUVmax and SUVmean were 14.2±3.8 and 8.9±2.2 g/mL, respectively. SUVmax and SUVmean were both significantly different between the bone metastases and osteoarthritic groups (p≤0.0001). Using a SUVmax cutoff of 19.5 g/mL for prostate cancer bone metastases in the spine and pelvis, sensitivity, specificity, positive and negative predictive values were 87%, 92%, 99% and 49%, respectively. Conclusion: This study showed significant differences in quantitative 99mTc-DPD uptake on bone SPECT/CT between prostate cancer bone metastases and spinal and pelvic osteoarthritic changes, with higher SUVmax and SUVmean in metastases. Using a SUVmax cutoff of 19.5 g/mL, high specificity and positive predictive value for metastases identification in the spine and pelvis were found, thus increasing accuracy of bone scintigraphy.

show abstract

⁶⁸Ga‐PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature

Cited by 61 publications

References 74 publications

Phase I Study of CTT1057, an ¹⁸F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Phase I Study of CTT1057, an ¹⁸F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Quantitative Bone SPECT/CT: High Specificity for Identification of Prostate Cancer Bone Metastases

Contact Info

Product

Resources

About

68Ga‐PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature

Cited by 61 publications

References 74 publications

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

Quantitative Bone SPECT/CT: High Specificity for Identification of Prostate Cancer Bone Metastases

Contact Info

Product

Resources

About

⁶⁸Ga‐PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature

Phase I Study of CTT1057, an ¹⁸F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Phase I Study of CTT1057, an ¹⁸F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer